- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02117934
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
March 18, 2019 updated by: Dynavax Technologies Corporation
A Phase 3, Observer-Blinded, Randomized, Active-Controlled (Engerix-B), Multicenter Trial of the Safety and Immunogenicity of HEPLISAV in Adults 18 to 70 Years of Age
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
8374
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35211
- Clinical Research Advantage, Inc.
-
-
Arizona
-
Chandler, Arizona, United States, 85224
- Radiant Research
-
Chandler, Arizona, United States, 85224
- Clinical Research Advantage, Inc.
-
Glendale, Arizona, United States, 85306
- Clinical Research Advantage, Inc.
-
Mesa, Arizona, United States, 85213
- Clinical Research Advantage, Inc.
-
Mesa, Arizona, United States, 85206
- Clinical Research Advantage, Inc.
-
Phoenix, Arizona, United States, 85020
- Clinical Research Advantage, Inc.
-
Phoenix, Arizona, United States, 85018
- Clinical Research Advantage, Inc.
-
Phoenix, Arizona, United States, 85050
- Clinical Research Advantage, Inc.
-
Scottsdale, Arizona, United States, 85251
- Radiant Research
-
Tempe, Arizona, United States, 85283
- Clinical Research Advantage, Inc.
-
Tucson, Arizona, United States, 85712
- Radiant Research
-
Tucson, Arizona, United States, 85741
- Clinical Research Advantage, Inc.
-
-
California
-
Santa Rosa, California, United States, 95405
- Radiant Research
-
Vista, California, United States, 92083
- Clinical Research Advantage, Inc.
-
-
Colorado
-
Centennial, Colorado, United States, 80112
- Clinical Research Advantage, Inc.
-
Colorado Springs, Colorado, United States, 80922
- Clinical Research Advantage, Inc.
-
Denver, Colorado, United States, 80239
- Radiant Research
-
-
Florida
-
Pinellas Park, Florida, United States, 33781
- Radiant Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Radiant Research
-
-
Illinois
-
Chicago, Illinois, United States, 60654
- Radiant Research
-
-
Indiana
-
Evansville, Indiana, United States, 47725
- Clinical Research Advantage, Inc
-
-
Iowa
-
Council Bluffs, Iowa, United States, 51503
- Clinical Research Advantage, Inc.
-
-
Minnesota
-
Edina, Minnesota, United States, 55435
- Radiant Research
-
-
Missouri
-
Saint Louis, Missouri, United States, 83141
- Radiant Research
-
-
Nebraska
-
Elkhorn, Nebraska, United States, 68022
- Clinical Research Advantage, Inc.
-
Fremont, Nebraska, United States, 68025
- Clinical Research Advantage, Inc.
-
Omaha, Nebraska, United States, 68124
- Clinical Research Advantage, Inc.
-
-
Nevada
-
Henderson, Nevada, United States, 89052
- Clinical Research Advantage, Inc.
-
Las Vegas, Nevada, United States, 89128
- Clinical Research Advantage, Inc.
-
-
Ohio
-
Akron, Ohio, United States, 44311
- Radiant Research
-
Cincinnati, Ohio, United States, 45249
- Radiant Research
-
Columbus, Ohio, United States, 43212
- Radiant Research
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- Radiant Research
-
Anderson, South Carolina, United States, 29621
- Clinical Research Advantage, Inc.
-
Greer, South Carolina, United States, 29650
- Radiant Research
-
-
Texas
-
Dallas, Texas, United States, 75231
- Radiant Research
-
Plano, Texas, United States, 75093
- Clinical Research Advantage, Inc.
-
San Antonio, Texas, United States, 78229
- Radiant Research
-
-
Utah
-
Murray, Utah, United States, 84123
- Radiant Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
A subject must meet all of the following criteria to be eligible for the trial:
Inclusion Criteria:
- Be 18-70 years of age, inclusive
- Able to comprehend and follow all required study procedures and be available for all visits scheduled in the study
- If a woman is of childbearing potential, she must consistently use an acceptable method of contraception or confirm in writing she will abstain from sexual activity from the Screening Visit through Week 28.
- Able and willing to provide informed consent
A subject with any one of the following criteria is not eligible for the trial:
Exclusion Criteria:
- Previous receipt of any hepatitis B vaccine
- History of hepatitis B or human immunodeficiency virus (HIV) infection or positive test for HBsAg, anti-HBs, antibody to hepatitis B core antigen (anti-HBc), or antibody to HIV
- History of autoimmune disorder
- History of sensitivity to any component of study vaccines
Has received the following prior to the first injection:
Within 28 days:
- Any vaccine
- Systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immune suppressive medication
- Granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF)
- Any other investigational medicinal agent
- Within 90 days: Blood products or immunoglobulin
- At any time: An injection of DNA plasmids or oligonucleotide
- If female: Pregnant, nursing, or planning to become pregnant during the trial
- Is undergoing chemotherapy or expected to receive chemotherapy during the study period; has a diagnosis of cancer within the last 5 years other than squamous or basal cell carcinoma of the skin
- Any other medical condition considered by the investigator likely to interfere with the subject's compliance or the interpretation of study assessments
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HEPLISAV
0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and placebo (saline injection) at Week 24, followed by a 52-week safety follow-up from the last active dose of HEPLISAV.
|
Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
Other Names:
|
Active Comparator: Engerix-B
1.0 mL Engerix-B (20 mcg HBsAg adsorbed on 500 mcg of aluminum hydroxide) administered intramuscularly in the deltoid muscle at Weeks 0, 4, and 24, followed by a 32-week safety follow-up from the last dose of Engerix-B.
|
Intramuscular injections at Week 0, Week 4, and Week 24
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Subjects Reporting Clinically Significant Adverse Events - Medically-attended Adverse Events, Serious Adverse Events, and Immune-mediated Adverse Events of Special Interest
Time Frame: Week 56
|
The percentage of participants with Medically-attended adverse events (MAEs), Serious Adverse Events (SAEs), and immune-mediated Adverse Events of Special Interest (AESIs).
MAEs are Adverse events (AEs) for which a subject sought medical attention at a doctor's office, clinic or study site, or emergency room, or was hospitalized.
SAEs are AEs that met the definition of Serious per FDA regulations.
Immune-mediated AESIs are AEs that were confirmed to be autoimmune in etiology.
|
Week 56
|
Percentage of Subjects With Type 2 Diabetes Mellitus Who Have a Seroprotective Immune Response
Time Frame: Week 28
|
Percentage of subjects with type 2 diabetes mellitus who have a seroprotective immune response (anti-HBs ≥ 10 milli-international unit (mIU)/mL) who receive HEPLISAV compared with subjects who receive Engerix-B
|
Week 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Robert Janssen, MD, Dynavax Technologies Corporation
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hyer RN, Janssen RS. Immunogenicity and safety of a 2-dose hepatitis B vaccine, HBsAg/CpG 1018, in persons with diabetes mellitus aged 60-70 years. Vaccine. 2019 Sep 16;37(39):5854-5861. doi: 10.1016/j.vaccine.2019.08.005. Epub 2019 Aug 17.
- Jackson S, Lentino J, Kopp J, Murray L, Ellison W, Rhee M, Shockey G, Akella L, Erby K, Heyward WL, Janssen RS; HBV-23 Study Group. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. Vaccine. 2018 Jan 29;36(5):668-674. doi: 10.1016/j.vaccine.2017.12.038. Epub 2017 Dec 27.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2014
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
October 1, 2015
Study Registration Dates
First Submitted
April 15, 2014
First Submitted That Met QC Criteria
April 17, 2014
First Posted (Estimate)
April 21, 2014
Study Record Updates
Last Update Posted (Actual)
March 20, 2019
Last Update Submitted That Met QC Criteria
March 18, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DV2-HBV-23
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on HEPLISAV
-
Baylor Research InstituteCompleted
-
Dynavax Technologies CorporationCompletedHepatitis BUnited States
-
National Institute of Allergy and Infectious Diseases...Dynavax Technologies CorporationActive, not recruitingHIV Infection | Hepatitis BUnited States, Haiti, Botswana, Philippines, Thailand, Brazil, Kenya, Malawi, India, South Africa, Uganda, Vietnam
-
Dynavax Technologies CorporationBaylor Research InstituteCompleted
-
Dynavax Technologies CorporationPPD, Part of Thermo Fisher ScientificActive, not recruiting
-
Universitätsklinikum Hamburg-EppendorfHelmholtz Zentrum München; LMU Klinikum; German Center for Infection Research; Medical... and other collaboratorsRecruitingChronic Hepatitis BGermany
-
Dynavax Technologies CorporationUnknownEnd Stage Renal Disease on Dialysis (Diagnosis)United States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHepatitis | Safety and TolerabilityUnited States
-
Mercy Medical CenterRecruitingHepatitis B | Cirrhosis, Liver | Chronic Liver DiseaseUnited States
-
Dynavax Technologies CorporationCompletedHepatitis BGermany, Canada